BioScience Trends. 2017;11(6):606-611. (DOI: 10.5582/bst.2017.01293)
Direct-acting agents for hepatitis C virus before and after liver transplantation.
Sugawara Y, Hibi T
Chronic hepatitis C virus (HCV) infection remains a widespread public health concern and many people are infected with HCV. HCV is one of the leading indications for liver transplantation. Direct-acting antiviral agents (DAAs) against HCV have changed the course of chronic HCV infection, however, making it a curable disease. DAA treatment may be initiated before or after liver transplantation. In the present review, we present the available data on DAA treatment of HCV in liver transplant recipients.
KEYWORDS: Liver transplantation, living donor, hepatocellular carcinoma